Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biochem Biophys Res Commun ; 435(1): 69-75, 2013 May 24.
Artigo em Inglês | MEDLINE | ID: mdl-23611777

RESUMO

Pinocembrin (5,7-dihydroxyflavanone) is one of the primary flavonoids in propolis. Angiotensin II (AngII) is a biologically active peptide that induces vasoconstriction via the activation of the angiotensin type 1 receptor (AT1R). In the present study, we investigated the vasorelaxant effect of pinocembrin on AngII-induced vasoconstriction and the molecular mechanism of action. Pinocembrin was observed to inhibit AngII-induced vasoconstriction in rat aortic rings with either intact or denuded endothelium. In endothelium-denuded tissues, pinocembrin (pD́'2pD2(') 4.28±0.15) counteracted the contractions evoked by cumulative concentrations of AngII. In a docking model, pinocembrin showed effective binding at the active site of AT1R. Pinocembrin was shown to inhibit both AngII-induced Ca(2+) release from internal stores and Ca(2+) influx. Moreover, the increase in the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and myosin light chain 2 (MLC2) induced by AngII was blocked by pinocembrin. These results demonstrate that pinocembrin inhibits AngII-induced rat aortic ring contraction, and these inhibitory effects may be related to the reduction of the AngII-induced increase in [Ca(2+)]i and ERK1/2 activation via blocking AT1R.


Assuntos
Aorta Torácica/fisiologia , Cálcio/metabolismo , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Flavanonas/farmacologia , Receptor Tipo 1 de Angiotensina/metabolismo , Vasoconstrição/efeitos dos fármacos , Angiotensina II/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/metabolismo , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Animais , Aorta Torácica/citologia , Aorta Torácica/metabolismo , Western Blotting , Miosinas Cardíacas/metabolismo , Células Cultivadas , Relação Dose-Resposta a Droga , Endotélio Vascular/fisiologia , Ativação Enzimática/efeitos dos fármacos , Flavanonas/metabolismo , Técnicas In Vitro , Masculino , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Músculo Liso Vascular/citologia , Músculo Liso Vascular/metabolismo , Miócitos de Músculo Liso/efeitos dos fármacos , Miócitos de Músculo Liso/metabolismo , Cadeias Leves de Miosina/metabolismo , Fosforilação/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
2.
Biochem Biophys Res Commun ; 421(3): 479-83, 2012 May 11.
Artigo em Inglês | MEDLINE | ID: mdl-22516750

RESUMO

Salvianolic acid A (Sal A) is a polyphenol extracted from the root of the Salvia miltiorrhiza bunge. Hydrogen peroxide (H(2)O(2)) is a major reactive oxygen species (ROS), which has been implicated in stroke and other neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In this study, we investigated the neuroprotective effects of Sal A in human SH-SY5Y neuroblastoma cells against H(2)O(2)-induced injury. Our results showed that cells pretreated with Sal A exhibited enhanced neuronal survival and that this protection was associated with an increase in adenosine triphosphate (ATP) and the stabilization of mitochondrial membrane potential. In addition, Sal A markedly decreased the excessive activation AMP-activated protein kinase (AMPK) and the serine-threonine protein kinase, Akt, in SH-SY5Ycells induced by H(2)O(2). In conclusion, our results demonstrated that Sal A protects SH-SY5Y cells against H(2)O(2)-induced oxidative stress and these protective effects are related to stress tolerance and not energy depletion via inhibition of the AMPK and Akt signaling pathway.


Assuntos
Ácidos Cafeicos/farmacologia , Citoproteção , Lactatos/farmacologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Quinases Proteína-Quinases Ativadas por AMP , Linhagem Celular Tumoral , Metabolismo Energético/efeitos dos fármacos , Humanos , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Neurônios/fisiologia , Proteínas Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Água/farmacologia
3.
J Asian Nat Prod Res ; 14(1): 46-54, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22263593

RESUMO

The purpose of the present study was to investigate the effect of formononetin and the related mechanisms on isolated rat thoracic aorta. Formononetin concentration dependently relaxed aortic rings precontracted with norepinephrine (NE, 1 µM) or KCl (80 mM). Pretreatment with formononetin noncompetitively inhibited contractile responses of aortas to NE and KCl. The vasorelaxant effect of formononetin partially relied on intact endothelia, which was significantly attenuated by incubation with N(ω)-nitro-L-arginine methyl ester (100 µM). In endothelium-denuded rings, glibenclamide (10 µM) and tetraethylammonium (5 mM) showed slight reduction in the vasorelaxant effect of formononetin. Moreover, formononetin reduced NE-induced transient contraction in Ca²âº-free solution and inhibited the vasocontraction induced by increasing external calcium in medium plus 80 mM KCl. Our results suggested that formononetin induced relaxation in rat aortic rings through an endothelium-dependent manner via nitric oxide synthesis pathway, and also involving an endothelium-independent vasodilatation by the blockade of Ca²âº channels. The opening of K⁺ channels might also be one of the mechanisms of formononetin-induced vasorelaxation.


Assuntos
Aorta Torácica/efeitos dos fármacos , Canais de Cálcio/metabolismo , Isoflavonas/farmacologia , Canais de Potássio/metabolismo , Vasodilatadores/farmacologia , Animais , Cálcio/metabolismo , Relação Dose-Resposta a Droga , Isoflavonas/química , Estrutura Molecular , Músculo Liso Vascular/efeitos dos fármacos , NG-Nitroarginina Metil Éster/farmacologia , Norepinefrina/metabolismo , Cloreto de Potássio/farmacologia , Ratos , Vasodilatação/efeitos dos fármacos
4.
Yao Xue Xue Bao ; 47(5): 604-8, 2012 May.
Artigo em Chinês | MEDLINE | ID: mdl-22812003

RESUMO

Effects of the effective components group of Xiaoshuantongluo formula (XECG) on rat acute blood stasis model were studied under the guidance of the concept of effective components group. Rat acute blood stasis model was induced by subcutaneous injection of epinephrine combined with ice water bath. Hemorheology indices such as whole blood viscosity, plasma viscosity, erythrocyte aggregation index and platelet aggregation rate; coagulation parameters including PT, APTT, TT and FIB; 6-keto-PGF1alpha, TXB2 and D-dimer levels were determined to evaluate the effects of XECG. The results showed that XECG significantly reduced ADP-induced platelet aggregation, but showed little influence on the whole blood viscosity, plasma viscosity and erythrocyte aggregation rate. XECG extended PT and TT slightly, but had no effects on APTT and FIB content. D-dimer levels significantly decreased after administration of XECG with a little decrease of TXB2, but the content of 6-keto-PGF1alpha did not change significantly. The results suggest that the role of XECG of anti-aggregation is more prominent.


Assuntos
Transtornos da Coagulação Sanguínea/sangue , Coagulação Sanguínea/efeitos dos fármacos , Viscosidade Sanguínea/efeitos dos fármacos , Medicamentos de Ervas Chinesas/farmacologia , Agregação Eritrocítica/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , 6-Cetoprostaglandina F1 alfa/sangue , Animais , Combinação de Medicamentos , Medicamentos de Ervas Chinesas/isolamento & purificação , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Hemorreologia/efeitos dos fármacos , Masculino , Tempo de Tromboplastina Parcial , Plantas Medicinais/química , Tempo de Protrombina , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Tempo de Trombina , Tromboxano B2/sangue
5.
Yao Xue Xue Bao ; 46(6): 642-9, 2011 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-21882523

RESUMO

There are growing evidences that pinocembrin has better neuroprotective effect. In the present study, the effect of pinocembrin on mitochondrial respiratory function was evaluated in global brain ischemia/ reperfusion (4-vessel occlusion, 4-VO) rats. The results showed that pinocembrin improved the respiratory activity of 4-VO brain mitochondria, through increasing ADP/O, state 3 respiration state (V3), respiration control rate index (RCI) and oxidative phosphorylation rate (OPR). And then, the effect of pinocembrin on brain mitochondria was verified in vitro. The results showed that pinocembrin increased ADP/O, state 3 respiration state, respiration control rate index, oxidative phosphorylation rate in NADH/FADH2 dependent respiratory chain and decreased state 4 respiration state (V4) in NADH dependent respiratory chain. Pinocembrin improved ATP content in brain mitochondria in vitro and in SH-SY5Y cells.


Assuntos
Trifosfato de Adenosina/biossíntese , Isquemia Encefálica/fisiopatologia , Respiração Celular/efeitos dos fármacos , Flavanonas/farmacologia , Mitocôndrias/fisiologia , Difosfato de Adenosina/metabolismo , Animais , Isquemia Encefálica/patologia , Linhagem Celular Tumoral , Hipocampo/patologia , Masculino , Mitocôndrias/efeitos dos fármacos , Neuroblastoma/metabolismo , Neuroblastoma/patologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Oxigênio/metabolismo , Ratos , Ratos Sprague-Dawley
6.
Yao Xue Xue Bao ; 45(6): 801-6, 2010 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-20939194

RESUMO

The aim of this study is to investigate the effects of the metformin on the formation of hepatic fibrosis in type 2 diabetic rats and discuss its mechanism of liver-protecting activity. After SD rats were fed with high-fat and high-sucrose diet for four weeks, low-dose streptozotocin (STZ) was injected intraperitoneally to make the animal mode of type 2 diabetes. Then, all diabetic rats was fed with the high-fat diet and metformin (ig, 100 mg x kg(-1)) was given orally to metformin group for four months. After the last administration, fasting blood glucose was determined. The livers were removed to calculate the hepatic coefficient and to make HE and Picro acid-Sirius red staining, immunohistochemistry (alpha-SMA and TGFbeta1) and TUNEL staining in order to evaluate the effect of metformin on the hepatic fibrosis. The animal model of type 2 diabetes with hepatic fibrosis was successfully made. Metformin can significantly alleviate the lesions of hepatic steatosis and fibrosis, markedly reduce the expressions of alpha-SMA and TGFbeta1 in liver tissue of type 2 diabetic rats. However, TUNEL staining result suggested that metformin could not reduce apoptosis of hepatocytes. The results suggest that metformin can inhibit the formation of hepatic fibrosis in type 2 diabetes.


Assuntos
Diabetes Mellitus Tipo 2/patologia , Cirrose Hepática Experimental/tratamento farmacológico , Fígado/patologia , Metformina/farmacologia , Actinas/metabolismo , Animais , Apoptose/efeitos dos fármacos , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/etiologia , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/etiologia , Diabetes Mellitus Tipo 2/metabolismo , Dieta Hiperlipídica , Feminino , Hepatócitos/patologia , Hipoglicemiantes/farmacologia , Hipoglicemiantes/uso terapêutico , Fígado/metabolismo , Cirrose Hepática Experimental/metabolismo , Cirrose Hepática Experimental/patologia , Masculino , Metformina/uso terapêutico , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Estreptozocina , Fator de Crescimento Transformador beta1/metabolismo
7.
Sheng Li Ke Xue Jin Zhan ; 41(2): 95-9, 2010 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-21416993

RESUMO

Traditionally, cell death has been categorized into apoptosis or necrosis. However, a growing number of research indicates necroptosis, distinct from apoptosis and necrosis, contributes to a range of human diseases as a new mechanism of cell death. In order to achieve a better understanding of different cell death models and an improvement for development of new drugs associated with this pathway, the mechanism of necroptosis, the differences among apoptosis, necrosis and necroptosis, as well as the role of necroptosis in human diseases and its relation to discovery of drug targets, are discussed in this article.


Assuntos
Apoptose/fisiologia , Morte Celular/fisiologia , Necrose , Animais , Morte Celular/efeitos dos fármacos , Humanos
8.
Life Sci ; 88(11-12): 521-8, 2011 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-21262238

RESUMO

AIMS: The therapeutic effect of pinocembrin, together with the therapeutic time window, in the transient global cerebral ischemia/reperfusion (I/R) rats was investigated. MAIN METHODS: Adult male Sprague-Dawley rats were subjected to global cerebral ischemia for 20 min by four-vessel occlusion. Pinocembrin (1 and 5mg/kg) was administrated intravenously 30 min before ischemia and 30 min, 2h, 6h after reperfusion, respectively. Neurological scores, brain edema and histological examination by Nissl staining were employed to assess the neuronal injury after ischemia and the neuroprotection by pinocembrin. The activities of superoxide dismutase (SOD), myeloperoxidase (MPO) and the content of malondialdehyde (MDA) in brain tissue were tested by colorimetric assays. Alterations of neurotransmitters were determined by a high performance liquid chromatography-electrochemical method. KEY FINDINGS: Pinocembrin significantly ameliorated neurological deficits and brain edema, and alleviated the degree of hippocampal neuronal loss at 24h after global cerebral I/R with a broad therapeutic time window. It was found that treatment with pinocembrin reduced the compensatory increase of SOD activity and decreased the MDA level and MPO activity in a dose-dependent manner. The metabolic balance between excitatory and inhibitory amino acids was modulated by pinocembrin treatment. SIGNIFICANCE: These findings suggest that pinocembrin provides neuroprotection against global cerebral ischemic injury with a wide therapeutic time window, which may be attributed to its antioxidative, antiinflammatory and antiexcitotoxic effects.


Assuntos
Flavanonas/uso terapêutico , Ataque Isquêmico Transitório/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , Aminoácidos/metabolismo , Animais , Edema Encefálico/enzimologia , Edema Encefálico/etiologia , Edema Encefálico/patologia , Edema Encefálico/prevenção & controle , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Flavanonas/administração & dosagem , Injeções Intravenosas , Ataque Isquêmico Transitório/complicações , Ataque Isquêmico Transitório/enzimologia , Ataque Isquêmico Transitório/patologia , Masculino , Fármacos Neuroprotetores/administração & dosagem , Ratos , Ratos Sprague-Dawley , Traumatismo por Reperfusão/enzimologia , Traumatismo por Reperfusão/etiologia , Traumatismo por Reperfusão/patologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa